Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study

Endocrine sensitivity/resistance and ET partner were major determinants of outcome with CDK4/6i plus ET in HR+/HER2- ABC, informing individualized treatment selection and sequencing.

Authors

Institutions

Publication Details

Journal
The Breast
Published
2025-11-25
DOI
https://doi.org/10.1016/j.breast.2025.104665
Citations
1
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study

Jacek Jassem, Bartłomiej Tomasik, Joanna Kiszka, Joanna Streb et al.
1 citations
The Breast
Advanced Breast Cancer Therapies
1.52
article

Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study

Jacek Jassem, Bartłomiej Tomasik, Joanna Kiszka, Joanna Streb, Katarzyna Soter, Grzegorz Kade, Rodryg Ramlau, Iwona Danielewicz, Katarzyna Pogoda, Bogumiła Czartoryska-Arłukowicz, Justyna Żubrowska, Michał Bieńkowski, Marek Ziobro, Jolanta Smok-Kalwat, Aleksandra Łacko, Bartosz Szymanowski, Paulina Myśliwiec, Renata Duchnowska, Bartosz Kamil Sobocki, Maria Litwiniuk, Barbara Radecka, Piotr Lipiec, Michał Jurczyk, Aleksandra Grela-Wojewoda, Karolina Winsko-Szczęsnowicz, Ewa Kustra, Ewa Kalinka‐Warzocha, Tomasz Lewandowski, Joanna Hudała-Klecha, Marek Szwiec, A Balata, Agnieszka Kowalewska-Felczak, Anna Koriat-Błońska, Magdalena Szymanik-Resko, Magdalena Łobaza
article en
1 citations

Abstract

Endocrine sensitivity/resistance and ET partner were major determinants of outcome with CDK4/6i plus ET in HR+/HER2- ABC, informing individualized treatment selection and sequencing.

The BreastVol. 85
Poznan University of Medical Sciences (PL), Jagiellonian University (PL), National Academy of Medicine (US), Medical University of Białystok (PL), University of Opole (PL), University of Wrocław (PL), Wroclaw Medical University (PL), Greater Poland Cancer Center (PL), Zakłady Magnezytowe (Poland) (PL), Wojskowy Instytut Medycyny Lotniczej (PL), Holy Cross University (PL), Gdynia Maritime University (PL), Wroclaw Research Centre EIT+ (Poland) (PL), Polish Mother’s Memorial Hospital Research Institute (PL), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), University of Zielona Góra (PL), University of Warmia and Mazury in Olsztyn (PL), Gdańsk Medical University (PL)
Openalex Percentile: Top 12%
Advanced Breast Cancer Therapies
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.